
GUTS
Healthcare · Biotechnology · $12.0M market cap
$0.9000+0.09 (+10.8%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +18.2% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | -1.59 | -1.39 | +12.6% |
| Aug 10, 2026 | After the close | -0.15 | -0.12 | +20.0% |
| Apr 6, 2026 | Time not confirmed | -0.41 | 0.06 | +114.2% |
| Mar 24, 2026 | After the close | -0.18 | -0.07 | +61.1% |
| Nov 12, 2025 | After the close | -0.32 | -0.71 | -121.9% |
| Aug 12, 2025 | After the close | -0.36 | -0.57 | -58.3% |
| May 13, 2025 | After the close | -0.50 | -0.49 | +2.0% |
| Mar 3, 2025 | Time not confirmed | -0.42 | -0.52 | -23.8% |
| Nov 12, 2024 | After the close | -0.50 | -0.43 | +14.0% |
| Aug 14, 2024 | After the close | -0.46 | -0.36 | +21.7% |
| May 13, 2024 | After the close | -0.30 | -0.17 | +43.3% |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated…